""This was a multi-center clinical trial looking at an antisense oligonucleotide therapy for LRRK2-specific Parkinson's disease. The main goal was to examine the safety of delivering this therapy to patients, with the hope that if it proved safe, future studies could evaluate whether it might slow disease progression.""
""The study tested whether BIIB094 could safely reduce LRRK2 levels in people with Parkinson's disease. The results suggest it can be done without serious safety concerns.""
""Across both parts of the trial, the treatment was generally well tolerated. While adverse events were common, they were not serious, indicating a favorable safety profile for BIIB094.""
BIIB094 is an experimental drug targeting the LRRK2 gene, a major contributor to Parkinson's disease. A clinical trial demonstrated its safety in reducing LRRK2 levels among participants. The trial involved 82 participants, with some receiving a single dose and others receiving multiple doses. The treatment was well tolerated, and while adverse events occurred, they were not serious. The study aims to pave the way for future research on whether this therapy can slow disease progression in Parkinson's patients.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]